Acquired
Novo Nordisk (Ozempic)
David Rosenthal
Yep. Wow. There's a lot of power here. I think the only one we haven't talked about yet is counter-positioning, which is interesting. Maybe you can make an argument at the beginning there was because this could disrupt the insulin market, but I don't really think so.
0
💬
0
Comments
Log in to comment.
There are no comments yet.